ArticleScientific reports2019
Mimicking in-vivo exposures to drug combinations in-vitro: anti-tuberculosis drugs in lung lesions and the hollow fiber model of infection.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- Review
- Article
- A freely accessible, adaptable hollow-fiber setup to reproduce first-order absorption: illustration with linezolid cerebrospinal fluid pharmacokinetic data.Microbiology spectrum · 2025Article
- Effect of host microenvironment and bacterial lifestyles on antimicrobial sensitivity and implications for susceptibility testing.npj antimicrobials and resistance · 2025Review
- 3D bioprinting for the construction of drug testing models-development strategies and regulatory concerns.Frontiers in bioengineering and biotechnology · 2025Review
- Hollow Fiber Microreactor Combined with Digital Twin to Optimize the Antimicrobial Evaluation Process.Micromachines · 2024Article
- Using Hollow Fiber to Model Treatment of Antimicrobial-Resistant Organisms.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Microfluidic dose-response platform to track the dynamics of drug response in single mycobacterial cells.Scientific reports · 2022Article
- Culture-Free Enumeration ofMicroorganisms · 2022Article
- Field Grand Challenge Frontiers in Antibiotics.Frontiers in antibiotics · 2022Article
- Implications of drug-induced phenotypical resistance: Is isoniazid radicalizingFrontiers in antibiotics · 2022Article
- Improving the Drug Development Pipeline for Mycobacteria: Modelling Antibiotic Exposure in the Hollow Fibre Infection Model.Antibiotics (Basel, Switzerland) · 2021Review
- Experimental Validation of a Mathematical Framework to Simulate Antibiotics with Distinct Half-Lives Concurrently in an In Vitro Model.Antibiotics (Basel, Switzerland) · 2021Article
- Pharmacokinetics and pharmacodynamics in the treatment of cutaneous leishmaniasis - challenges and opportunities.RSC medicinal chemistry · 2021Review
- Novel 2D and 3D Assays to Determine the Activity of Anti-Leishmanial Drugs.Microorganisms · 2020Article
- Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy.Clinical pharmacokinetics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Here, we evaluate protocol requirements to mimic therapeutically relevant drug concentrations at the site of infection (i.e. lung lesion) in an in-vitro hollow fibre model of infection using pulmonary tuberculosis as a paradigm. Steady-state pharmacokinetic profiles in plasma, lung tissue and lung lesion homogenate were simulated for isoniazid, rifampicin and pyrazinamide and moxifloxacin. An R-shiny User Interface was developed to support conversion of in-vivo pharmacokinetic C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.